PRNewsWire
01 Jun 2026, 00:00 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-preliminary-poc-data-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-in-first-line-advanced-nsclc-302786452.html
Read source
Story key points
4 claims · impact-rated
IBI363 (TAK-928) showed a preliminary objective response rate (ORR) of 86.4% and a disease control rate (DCR) of 100% in the 3→1.5 mg/kg dose group for first-line advanced NSCLC. — High response rates in a first-line lung cancer setting are a major catalyst for biotech valuation and suggest strong potential for regulatory approval.
+0.80The drug demonstrated potent anti-tumor effects specifically in patients with PD-L1 negative or low expression (TPS < 50%), a group typically harder to treat with standard immunotherapies. — Expanding the addressable market to PD-L1 negative patients significantly increases the commercial potential of the drug.
+0.60Innovent has initiated a randomized head-to-head study comparing IBI363 combined with chemotherapy against the current standard of care, pembrolizumab combined with chemotherapy. — A head-to-head trial against the market leader is the critical path to gaining market share and achieving gold-standard status.
+0.50Continue reading
6 related stories
Search tags
The 3→1.5 mg/kg dose group showed a lower rate of Grade ≥3 treatment-related adverse events (65.2%) compared to higher fixed doses (82.1% and 93.1%). — Improving the safety profile relative to efficacy is essential for the drug's viability in clinical practice and regulatory approval.
+0.30Ticker attribution
Model heads
As a partner/co-developer of IBI363 (TAK-928), the positive clinical results for the drug are a significant win for Takeda.
The company reported highly positive preliminary efficacy data for its drug candidate IBI363 in the treatment of NSCLC.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
